In Situ Hybridization Market - Global Revenue Growth Expectations by 2025

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global in situ hybridization market. 

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. 

Global Market Size Estimation:

The size of the ISH market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.

The global in situ hybridization market size is projected to reach USD 1.3 billion by 2025 from USD 0.9 billion in 2020, at a CAGR of 7.4% during the forecast period.

The increasing incidence of cancer and genetic disorder and awareness of ISH based companion diagnostics tests are the major factors driving the growth of this market.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829

Hospitals & diagnostic laboratories accounted for the fastest-growing end user segment of the ISH market

Based on the end user, the in situ hybridization market is segmented into hospital & diagnostic laboratories, academic & research institutes, CROs, and pharmaceutical & biotechnology companies. The hospital & diagnostic laboratories segment accounted for the largest share of the ISH market in 2019. This can be attributed to the increasing number of molecule-based screening, increasing number of specialty diagnostic tests performed in hospital laboratories, the rising number of in-house diagnostic procedures, and the rising trend of establishing in-house diagnostic capabilities in hospitals.

Recent Developments:

# In 2020, RNAscope ISH Detection Kit (Bio-Techne) received CE-IVD approval for BOND-III platform (Leica Biosystems).
# In 2020, Creative Bioarray (US) launched 2019 Novel Coronavirus Detection FISH probes to detect viral particles in infected cells & tissues.
# In 2019, Roche launched VENTANA HER2 Dual ISH DNA Probe Cocktail assay.
# In 2019, Roche provided its platform for integration with Bio-Techne’s RNAscope ISH assay.
# In 2019, Agilent Technologies, the National University of Singapore, and the National University Hospital set up Singapore’s first integrated R&D facility.

North America accounted for the largest share of the ISH market

North America accounted for the largest share of the global market, followed by Europe. The large share of the North American region can be attributed to the presence of major players operating in the ISH market in the US, the rising incidence of cancer and infectious diseases, and the increasing adoption of CDx assay kits.

Report Objectives:

# To define, describe, segment, and forecast the in situ hybridization market based on product, application, end user, technology and region.

# To provide detailed information about the factors influencing market growth, such as drivers, opportunities, and challenges.

# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall in situ hybridization market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW).

# To profile the key players in the global in situ hybridization market and comprehensively analyze their core competencies and market rankings.

# To track and analyze competitive developments, such as product launches, expansions, and partnerships in the in situ hybridization market

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=212028829

Global Industry Leaders:

The key strategies adopted by the major players include new product development, mergers & acquisitions, expansion, partnerships, agreements, and collaborations with other players in the in-situ hybridization landscape to meet the demand of their end users.

Major players operating in the global in-situ hybridization market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and Agilent Technologies, Inc. (U.S.).